



## Avivagen to Exhibit Vivamune at SuperZoo

OTTAWA, June 22, 2018 -- Avivagen Inc. (TSXV:VIV) ("Avivagen" or the "Corporation"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it will be exhibiting Vivamune at booth 4083 at SuperZoo, one of the largest pet product trade shows in the world, from June 26<sup>th</sup>-28<sup>th</sup> in Las Vegas, Nevada.

As a must-see event for pet professionals from across the globe, SuperZoo introduces attendees to the pet industry's newest trends, insights and influential players within the marketplace. Vivamune will also be featured in the New Product Showcase and eligible for The Best New Pet Product Award. With over 10,000 attendees, SuperZoo represents the most-attended pet industry trade show in North America.

### About Avivagen

Avivagen Inc. is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit [www.avivagen.com](http://www.avivagen.com).

### About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen's OxC-beta™ technology arises from Avivagen's discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors. Specifically, Avivagen has discovered the naturally occurring compound that is the actual source of β-carotene's non-vitamin A activity and uses the synthetic version of the compound as the source of activity of Avivagen's OxC-beta™ products. Importantly, the OxC-beta™ compound is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand.

### About Vivamune™ Health Chews (Vivamune)

Vivamune is an all-in-one chew that can dramatically simplify a pet's supplement routine. Featuring a newly-discovered, novel immune-supporting active ingredient, OxC-beta™, Vivamune targets joints, skin and digestive health all in a single, tasty chew a pet will love. Vivamune is available for sale in the United States. For more information, visit [www.vivamunehealth.com](http://www.vivamunehealth.com).

### Forward Looking Statements

*This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipate", "appear", "believe", "consider", "could", "estimate", "expect", "if", "intend", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "pursue", "seem", "should", "whether", "will", "would" and similar expressions. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen's attendance at SuperZoo may not have the anticipated effect to increase sales of Vivamune in other jurisdictions or on Vivamune's overall sales due to many factors, many of which are outside of Avivagen's control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

### For more information:

Avivagen Inc.  
Drew Basek  
Director of Investor Relations  
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6  
Phone: 416-540-0733  
E-mail: [d.basek@avivagen.com](mailto:d.basek@avivagen.com)

Kym Anthony  
Chairman & Interim CEO  
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6  
Head Office Phone: 613-949-8164  
Website: [www.avivagen.com](http://www.avivagen.com)